BACKGROUND: To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced @entity788 ( @entity788 ). @entity1 AND METHODS: At total of 190 @entity1 were randomly assigned to receive @entity416 1000 mg/m(2) twice daily on days 1-14 plus @entity901 130 mg/m(2) on day 1 (CapOx), @entity416 825 mg/m(2) twice daily on days 1-14 plus @entity136 1000 mg/m(2) on days 1 and 8 (CapGem) or @entity136 1000 mg/m(2) on days 1 and 8 plus @entity901 130 mg/m(2) on day 8 (mGemOx). Treatment cycles were repeated every three weeks. The primary end point was progression-free survival (PFS) rate at 3 months; secondary end points included objective response rate, @entity1735 antigen 19-9 response, clinical benefit response, overall survival and @entity137 . RESULTS: The PFS rate after 3 months was 51% in the CapOx arm, 64% in the CapGem arm and 60% in the mGemOx arm. Median PFS was estimated with 4.2 months, 5.7 months and 3.9 months, respectively (P = 0.67). Corresponding median survival times were: 8.1 months (CapOx), 9.0 months (CapGem) and 6.9 months (mGemOx) (P = 0.56). Grade 3/4 hematological @entity137 were more frequent in the two Gem-containing arms; grade 3/4 non-hematological @entity137 rates did not exceed 15% in any arm. CONCLUSION: CapOx, CapGem and mGemOx have similar clinical efficacy in advanced @entity788 . Each regimen has a distinct but manageable tolerability profile.

XXXX plus @entity901 (CapOx) versus @entity416 plus @entity136 (CapGem) versus @entity136 plus @entity901 (mGemOx): final results of a multicenter randomized phase II trial in advanced @entity788 .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer', 'PC'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity416 :: (MESH:C110904,Chemical) :: ['Capecitabine']
